Bionano Genomics, Inc.
BNGO
$3.63
-$0.02-0.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.37% | -23.86% | -34.83% | -10.29% | 18.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.37% | -23.86% | -34.83% | -10.29% | 18.26% |
| Cost of Revenue | -40.81% | -42.70% | 121.02% | -18.38% | 11.23% |
| Gross Profit | 4.04% | 40.16% | -407.24% | 12.00% | 36.43% |
| SG&A Expenses | -54.21% | -95.48% | -61.99% | -57.09% | -21.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.91% | -76.68% | -36.57% | -50.78% | -20.28% |
| Operating Income | 68.28% | 96.76% | 37.03% | 59.73% | 27.99% |
| Income Before Tax | 90.16% | 54.19% | 60.70% | 58.34% | 15.25% |
| Income Tax Expenses | 138.89% | 102.78% | -38.46% | -21.21% | -169.23% |
| Earnings from Continuing Operations | 90.13% | 54.15% | 60.69% | 58.31% | 15.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.13% | 54.15% | 60.69% | 58.31% | 15.36% |
| EBIT | 68.28% | 96.76% | 37.03% | 59.73% | 27.99% |
| EBITDA | 74.69% | 105.38% | 47.46% | 64.44% | 30.13% |
| EPS Basic | 96.78% | 81.52% | 83.98% | 80.57% | 51.52% |
| Normalized Basic EPS | 96.26% | 95.11% | 73.46% | 77.29% | 57.41% |
| EPS Diluted | 96.78% | 81.52% | 83.98% | 80.57% | 51.56% |
| Normalized Diluted EPS | 96.26% | 95.11% | 73.46% | 77.29% | 57.41% |
| Average Basic Shares Outstanding | 206.48% | 148.09% | 145.32% | 114.55% | 74.61% |
| Average Diluted Shares Outstanding | 206.48% | 148.09% | 145.32% | 114.55% | 74.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |